37.5% of subjects received disease-modifying therapy (DMT) during the entire study (8.33% immunosuppressive treatments, 16.66% interferon beta, 4.16% glatiramer acetate and 8.33% fingolimod); 20.83% of them received therapies for MS symptoms management (i.e. spasticity, depression, pain). Here, IFNB1 is linked to depressive symptom measurement.